Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Transitional Cell 29Carcinoma, Non-Small-Cell Lung 29Urinary Bladder Neoplasms 26Neoplasms 22Carcinoma, Renal Cell 22Carcinoma, Merkel Cell 21Neoplasm Metastasis 18Colorectal Neoplasms 16Breast Neoplasms 16Squamous Cell Carcinoma of Head and Neck 15Ovarian Neoplasms 14Triple Negative Breast Neoplasms 11Pancreatic Neoplasms 9Melanoma 9Head and Neck Neoplasms 8Stomach Neoplasms 7Recurrence 6Carcinoma, Hepatocellular 6Ureteral Neoplasms 5Small Cell Lung Carcinoma 5Prostatic Neoplasms 5Urethral Neoplasms 4Sarcoma 4Neuroendocrine Tumors 4Leukemia, Myeloid, Acute 4Glioblastoma 4Carcinoma, Squamous Cell 4Uterine Cervical Neoplasms 3Turcot syndrome 3Skin Neoplasms 3

Interventions

Lenalidomide 4Gemcitabine 4Dexamethasone 4Cyclophosphamide 4Bortezomib 4Nivolumab 3Cisplatin 3Carboplatin 3vandetanib 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2pomalidomide 2pembrolizumab 2liposomal doxorubicin 2fludarabine 2durvalumab 2capivasertib 2Radiosurgery 2Paclitaxel 2Doxorubicin 2Bevacizumab 2Anthropogenic Effects 2venetoclax 1umbralisib 1ublituximab 1tremelimumab 1tivozanib 1ricolinostat 1regorafenib 1pazopanib 1niraparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Progression × avelumab × Clear all
NCT03990571 2024-10-18

Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

M.D. Anderson Cancer Center

Phase 2 Completed
40 enrolled 13 charts

Carcinoma, Adenoid Cystic, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡